预约演示
更新于：2026-08-21
Voglibose
伏格列波糖
更新于：2026-08-21
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C10H21NO7 |
InChIKeyFZNCGRZWXLXZSZ-CIQUZCHMSA-N |
CAS号83480-29-9 |
关联
84
项与 伏格列波糖 相关的临床试验CTR20262405
伏格列波糖口崩片生物等效性试验
CTR20252676
伏格列波糖口崩片人体生物等效性研究
CTRI/2025/04/085924
Study Of Efficacy And Safety Of Fixed Drug Combination Of Glimepiride, Metformin And Voglibose In Type 2 Diabetes Patients Inadequately Controlled On Dual Combination. - GLIVME
100 项与 伏格列波糖 相关的临床结果
登录后查看更多信息
100 项与 伏格列波糖 相关的转化医学
登录后查看更多信息
100 项与 伏格列波糖 相关的专利（医药）
登录后查看更多信息
547
项与 伏格列波糖 相关的文献（医药）2026-12-01JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN
Evaluation of novel topiramate–phenolic acid conjugates as potent pancreatic α-amylase inhibitors: in vitro and in silico insights
Article
作者: Sharma, Tripti ; Biswas, Abanish ; Chandra, Anshuman ; Padhy, Ipsa
Inhibition of carbohydrate digesting enzymes like pancreatic α-amylase has proven to be an effective strategy in countering postprandial hyperglycaemia. However, unwanted adverse effects associated with current therapies, such as ACB, voglibose, and miglitol, have necessitated the development of safer and more effective alternatives. These challenges have prompted growing interest in natural product scaffolds, particularly phenolic compounds, which exhibit favourable safety profiles and multifaceted enzyme inhibition. In this context, the strategic design of molecular conjugates integrating bioactive phenolics offers a promising route to enhance inhibitory potency, binding specificity, and therapeutic relevance. Reportedly, molecular hybrids with chalcone, phenolic acid, coumarin and polyphenol backbone exhibited impressive antioxidant and potent inhibition against digestive enzymes. In the quest of developing novel anti-hyperglycaemic agents, we report in vitro and in silico evaluation of the novel TPAC as potential pancreatic α-amylase inhibitors in the present work. Among the ten conjugates, T5 (IC50 = 50.65 ± 0.76 µM) exhibited strong inhibition against PPA which was comparable to positive control ACB (24.81 ± 0.98 µM). Computational binding analysis revealed binding of T5 to HPA (PDB ID: 2QV4) by interacting with the amino acid residues and distorting the receptor's catalytic site conformation. Furthermore, the conformational dynamic studies and electron density driven simulations established the stability and high reactivity of T5 within the ligand-receptor complex. The in silico studies corroborated the in vitro enzyme inhibition results, reinforcing the mechanistic insights into ligand-receptor interactions. Taken together, the experimental and computational results indicate that T5 merits further investigation as a candidate molecule targeting pancreatic α-amylase for the management of T2D .
2026-05-01EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Design, synthesis of novel methyl-glycosyl furanose based sulfonium type α-glucosidase inhibitors with potent antihyperglycemic activity
Article
作者: Xu, Bohang ; Xie, Weijia ; Tanabe, Genzoh ; Li, Yaojia ; Li, Wei ; Yao, Xuesong ; Li, Yu ; Sun, Xiaolian ; He, Xiaosong ; Muraoka, Osamu ; Jin, Shuqing
Developing effective α-glucosidase inhibitors is critical for managing hyperglycemia in individuals with high-carbohydrate diets; however, current drugs exhibit limitations in both efficacy and tolerability. In the present study, 25 derivatives of neoponkoranol, an active sulfonium type α-glucosidase inhibitor identified from Genus Salacia were synthesized. These compounds containing a methyl-glycosyl furanose scaffold modified with various hydrophobic groups at the 5'-O-position, were characterized using HRMS and NMR spectroscopy. Biological evaluations demonstrated a selectively enhanced maltase inhibition profile while maintaining broad-spectrum activity. Most sulfonium salts exhibited potent inhibitory activity against maltase and sucrase with IC50 values ranging from 0.14 to 2.21 μM; these potencies are comparable to or superior to those of the positive controls acarbose and voglibose. In addition, the designed derivatives also exhibited strong isomaltase inhibitory activities whereas acarbose was almost inactive against this enzyme. Compound LY-23 emerged as the most potent inhibitor with maltase IC50 = 0.18 ± 0.03 μM, sucrase IC50 = 0.14 ± 0.01 μM, and isomaltase IC50 = 0.51 ± 0.06 μM. Mechanism studies characterized LY-23 as a competitive inhibitor. Molecular docking along with 3D fluorescence and CD spectral analyses indicated that LY-23 binds to α-glucosidase, inducing secondary structural and conformational changes in the enzyme. Furthermore, LY-23 showed no significant cytotoxicity in HEK293T and L02 cells. Remarkably, in vivo studies revealed that the oral administration of LY-23 (1.0 or 10.0 mg/kg) effectively reduced postprandial blood glucose levels in normal ICR mice following maltose or sucrose loading, with an efficacy comparable to that of voglibose (1.0 mg/kg) and acarbose (20.0 mg/kg), respectively. These findings highlight LY-23 as a promising candidate for the development of novel α-glucosidase inhibitors with antihyperglycemic properties.
2026-04-06Cureus Journal of Medical Science
Effectiveness of Nutritional Therapy Versus Alpha-Glucosidase Inhibitors in Postprandial Glycemia Control in an Indian Subpopulation of Patients With Type 2 Diabetes: A Prospective Crossover Study
Article
作者: Hanchinal, Shivaraj S ; Shambhukari, Praveen Rao ; Gaddam, Anudeep
BACKGROUND:
Type 2 diabetes mellitus (T2DM) poses a significant global health challenge, impacting millions of people worldwide. While many studies focus on HbA1c levels, there remains a need to evaluate glycemic variability and postprandial glucose (PPG) excursions. Therefore, this study was conducted to assess and compare the safety and effectiveness of nutritional therapy and alpha-glucosidase inhibitors in achieving rapid PPG stabilization in an Indian subpopulation of patients with T2DM.
METHODS:
This short-term open-label study included T2DM patients uncontrolled on metformin and sulfonylurea. The study enrolled 60 participants (40 males, 20 females) with a mean age of 54.06 ± 6.04 years, with the majority being 30-60 years of age (85%). All patients were given intermittent medical nutritional therapy (low glycemic index (LGI) diet) and alpha-glucosidase inhibitors (AGIs; acarbose, voglibose) to manage postprandial glycemia. A rotational design ensured that each group experienced all interventions in varying sequences for a comprehensive analysis of their effects. Glycemic responses were assessed using finger-stick capillary glucose measurements and continuous glucose monitoring (CGM) to evaluate postprandial and 24-hour glycemic variability.
RESULTS:
Postprandial mean glucose levels were significantly reduced with all interventions (p<0.05), with the highest reduction observed with acarbose. Between AGIs, the adverse effects were similar between medications. The 24-hour mean glucose levels, mean amplitude of glycemic excursion, and area under the curve for 24-hour glycemic fluctuations were significantly lower with interventions, especially acarbose.
CONCLUSION:
We conclude that AGIs and LGI diets effectively reduce postprandial glucose, especially in Indian T2DM patients consuming high-carbohydrate diets with a high glycemic load.
100 项与 伏格列波糖 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 糖尿病 | 中国 | 2001-01-01 | |
| 糖尿病 | 中国 | 2001-01-01 | |
| 2型糖尿病 | 日本 | 1994-07-01 | |
| 高血糖 | 日本 | 1994-07-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 葡萄糖耐受不良 | 临床阶段不明 | 中国 | 2008-07-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 494 | 簾獵醖遞夢構製鬱積願(糧齋壓遞網鑰範膚衊餘) = 窪夢觸鏇顧糧選鹹簾簾 繭襯獵選鑰範襯壓選網 (衊築襯製鏇積鏇鏇蓋觸, 0.0742) 更多 | - | 2019-02-04 | |||
簾獵醖遞夢構製鬱積願(糧齋壓遞網鑰範膚衊餘) = 網憲蓋膚餘壓製鬱糧壓 繭襯獵選鑰範襯壓選網 (衊築襯製鏇積鏇鏇蓋觸, 0.0764) 更多 | |||||||
临床4期 | 197 | 願壓膚鑰願窪範餘齋鬱 = 鏇襯鏇遞範簾艱選夢艱 簾鹽繭夢齋窪網淵選齋 (網鏇蓋膚繭夢鑰鏇衊醖, 願鬱鑰獵廠餘積觸鏇淵 ~ 窪繭憲廠淵繭鏇壓夢鑰) 更多 | - | 2015-04-09 | |||
临床1期 | - | 22 | Metformin | 窪艱蓋衊鑰鹽獵糧淵鏇(壓選選鹹鬱觸遞繭簾願): geometric mean ratio = 0.99 (90% CI, 0.92 ~ 1.06), P-Value = > 0.05 更多 | - | 2014-11-01 | |
Metformin + Voglibose | |||||||
临床3期 | 133 | Sitagliptin 50 mg/day | 鬱蓋願繭築鑰壓願網壓(獵鏇窪遞夢鹽獵製選蓋) = 積鬱餘願憲遞鹹鑰衊憲 網衊網齋糧築遞製繭窪 (獵繭壓觸餘觸鬱選艱鹽 ) 更多 | - | 2013-11-27 | ||
临床3期 | 319 | Sitagliptin 50 mg once daily | 選鑰簾襯選鬱廠艱獵網(繭獵蓋艱鏇築顧膚鬱鏇) = 鏇壓選夢簾夢廠觸憲淵 窪齋淵鬱窪齋鏇壓鑰鹹 (願糧蓋餘鏇鏇壓窪膚網, -0.8 ~ -0.6) 更多 | 积极 | 2010-07-01 | ||
Voglibose 0.2 mg thrice daily | 選鑰簾襯選鬱廠艱獵網(繭獵蓋艱鏇築顧膚鬱鏇) = 築憲遞網鹹齋鬱鏇衊鬱 窪齋淵鬱窪齋鏇壓鑰鹹 (願糧蓋餘鏇鏇壓窪膚網, -0.4 ~ -0.2) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用